Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03859921

Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET

This randomised double-blinded controlled trial aims to compare the live birth rate in natural FET cycles with and without oral dydrogesterone as luteal phase support. The hypothesis is that the use of oral dydrogesterone will increase the live birth rate of natural cycle FET.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–42 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Department of Obstetrics and Gynaecology

Hong Kong, China

Location status: Recruiting

Location contact

Ernest HY NG, MD

CONTACT

[email protected]

852-22553400

Ernest HY NG, MD

PRINCIPAL_INVESTIGATOR

About this study

Trial design:

Women undergoing FET in the Centre of Assisted Reproduction and Embryology, The University of Hong Kong-Queen Mary Hospital, will be recruited and will be randomized into one of the following two study groups:

Treatment group: Oral dydrogesterone 10mg tds will be given for two weeks from the next day of the LH surge or hCG induced ovulation.

Control group: Placebo will be given given for two weeks from the next day of the LH surge or hCG induced ovulation.

Treatment of subjects

Ovarian stimulation protocol:

All women received ovarian stimulation according to the standard protocol of the Centre. Egg collection is carried out 36 hours after the HCG trigger. One to two early cleaving embryos or blastocysts will be transferred and any excess good quality cleaving embryos or blastocyst will be frozen two to six days after egg collection.

FET cycle:

FET is carried out at least 2 month after the stimulated cycle if the patient fails to get pregnant in the stimulated IVF cycle. Frozen cleaving embryos or blastocysts after thawing are transferred in natural cycles for those women having regular ovulatory cycles. Women are monitored daily from 18 days before the expected date of he next period for pelvic ultrasound assessment of the size of the leading follicle and determination of serum oestradiol (E2) and LH concentrations until the LH surge, which is defined by the LH level being above 20 IU/L and more than double of the average of the LH levels over the past three days. HCG can also be given when the leading follicle reaches 17mm in diameter.

Women will be counseled by a designated research nurse who will explain the purpose of this study when they first attend the clinic for FET. On the day of the hCG trigger or one day after the LH surge, those who consent to join the study will be randomized into one of the two study arms specified in an opaque envelope according to a computer-generated randomization list prepared by a research nurse who is not involved in the present study. Oral dydrogesterone and placebo tablets have the same appearance and will be started one day after the hCG trigger or the LH surge for two weeks.

The transfer is performed on the third day after the LH surge or the fourth day after the hCG trigger for frozen cleaving embryos (on the sixth day after the LH surge or the seventh day after hCG trigger for frozen blastocysts). Again 1-2 cleaving embryos are replaced according to our standard protocol. A urine pregnancy test will be performed 16 days after the FET. In case of pregnancy, the outcome of pregnancy will be traced afterwards and used for analysis. Luteal phase support is not required in those who get pregnant.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age of women <43 years at the time of stimulated IVF
  • Replacing early cleavage embryos or blastocysts after thawing

Exclusion criteria

  • Requiring hormonal replacement cycles
  • Use of donor oocytes or embryos
  • Undergoing preimplantation genetic testing
  • Presence of hydrosalpinx not corrected surgically prior to FET
  • Refusal to join the study

Treatment and study plan

Dydrogesterone

Drug

Progesterone

Other names: Duphaston

Placebo

Drug

Placebo with appearance similar to Dydrogesterone

Primary outcomes

  1. live birth rate

    Time frame: 10 months after recruitment

    the number of live birth beyond 22 weeks gestation per transfer cycle

Secondary outcomes

  1. Clinical pregnancy rate

    Time frame: 6 weeks of gestation after recruitment

    the number of women with an intrauterine gestational sac at 5-6 weeks of gestation

  2. Ongoing pregnancy rate

    Time frame: 10 weeks of gestation after recruitment

    the number of intrauterine pregnancies with fetal pulsation beyond 10 gestation per transfer cycle

  3. Pregnancy loss per number of transfer cycles

    Time frame: less than 22 weeks of gestation

    Miscarriage

Study contacts

Contact information is provided by the study sponsor or research team.

Ernest HY Ng, MD

CONTACT

[email protected]

852-28553400

Sponsors and collaborators

Lead sponsor

The University of Hong Kong

Other

Registry information

Official study title

A Randomized Double Blind Controlled Comparison of Oral Dydrogesterone as Luteal Phase Support in Natural Cycle Frozen-thawed Embryo Transfer

Important dates

Study start
2021
Primary completion
2025
Study completion
2026
First posted
Mar 1, 2019
Registry last updated
Jun 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.